VP7-2022: An ad-hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): A double-blind, randomized, placebo-controlled, phase III trial

Mansoor Raza Mirza ,J Dong,J Liu,Y Huang,Y Gao,R Yin,X Zhen,J Zhu,J Wang,J Yang,D Wang,X Wu,J Hou,Z Liu,H Yang,Q Zhou,L Wu,B Kong,G Lou,L Chen

doi:10.1016/j.annonc.2022.11.007

VP7-2022: An ad-hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): A double-blind, randomized, placebo-controlled, phase III trial

Mansoor Raza Mirza , J Dong + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.11.007

Copy DOI

Journal: Annals of Oncology	Publication Date: Dec 15, 2022
Citations: 7	License type: publisher-specific-oa

#Platinum-sensitive Recurrent Ovarian Cancer #Maintenance Therapy In Patients + Show 4 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Niraparib has previously shown efficacy in a phase 3 NORA trial, which demonstrated significantly improved PFS in patients with platinum-sensitive recurrent ovarian cancer (PSROC). The aim of this ad hoc interim analysis is to investigate the effect of niraparib on OS with individualized starting dose (ISD).

Full Text